Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionSegall Bryant & Hamill, Llc
Latest Disclosed Ownership2,000 shares
Latest Disclosed Value $ 640,860
Segall Bryant & Hamill, Llc ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Segall Bryant & Hamill, Llc filed a 13F-HR form disclosing ownership of 2,000 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $571,400 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 9, 2023 disclosing 0 shares of Alnylam Pharmaceuticals, Inc.. The current value of the position is $521,000 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 2,000 641 0.0104
2023-11-09 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,000 -100.00 0 -100.00
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 380 0.0040
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 0 -100.00 0.0043
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 475 18.75 0.0053
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 2,000 0 0.00 400 36.99 0.0048
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 292 -10.70 0.0033
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 327 -3.54 0.0031
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 339 -10.32 0.0031
2021-12-30 2021-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 378 11.50 0.0036
2021-11-03 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 378 0.0037
2021-08-12 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 -9 -0.45 339 19.79 0.0033
2021-05-13 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,009 0 0.00 283 8.43 0.0028
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,009 0 0.00 261 -10.62 0.0029
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,009 9 0.45 292 -1.35 0.0040
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 296 35.78 0.0050
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 218 -5.22 0.0044
2020-02-11 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 2,000 230 0.0036
2018-08-08 2018-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 0 -2,000 -100.00 0 -100.00
2018-05-15 2018-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 2,000 0 0.00 238 -6.30 0.0055
2018-02-15 2017-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 2,000 0 0.00 254 8.09 0.0056
2017-11-14 2017-09-30 13F Alnylam Pharmaceuticals -Common Stock 02043Q107 2,000 2,000 235 0.0055
2016-05-12 2016-03-31 13F Alnylam Pharmaceuticals -Common Stock 02043Q107 0 0 0 0.0000
2016-02-12 2015-12-31 13F Alnylam Pharmaceuticals -Common Stock 02043Q107 0 0 0 0.0000
2015-11-12 2015-09-30 13F Alnylam Pharmaceuticals -Common Stock 02043Q107 0 -2,000 -100.00 0 -100.00
2015-08-12 2015-06-30 13F Alnylam Pharmaceuticals -Common Stock 02043Q107 2,000 0 0.00 240 14.83 0.0054
2015-05-14 2015-03-31 13F Alnylam Pharmaceuticals -Common Stock 02043Q107 2,000 2,000 209 0.0047
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.